The complex bacterial populations that constitute the gut microbiota can harbor antibiotic-15 resistance genes (ARGs), including those encoding for β-lactamase enzymes (BLA), which 16 degrade commonly prescribed antibiotics such as ampicillin. While it is known that ARGs can be 17 transferred between bacterial species, with dramatic public health implications, whether 18 expression of such genes by harmless commensal bacterial species shields antibiotic-sensitive 19 pathogens in trans by destroying antibiotics in the intestinal lumen is unknown. To address this 20 question, we colonized GF mice with a model intestinal commensal strain of E. coli that 21 produces either functional or defective BLA. Mice were subsequently infected with Listeria 22
monocytogenes or Clostridioides difficile followed by treatment with oral ampicillin. Production 23 of functional BLA by commensal E. coli markedly reduced clearance of these pathogens and 24 enhanced systemic dissemination during ampicillin treatment. Pathogen resistance was 25 independent of ARG acquisition via horizontal gene transfer but instead relied on antibiotic 26 degradation in the intestinal lumen by BLA. We conclude that commensal bacteria that have 27 acquired ARGs can mediate shielding of pathogens from the bactericidal effects of antibiotics. 28 29 Importance 30
The wide use of antibiotics in human populations and in livestock has led to increasing 31 prevalence of pathogenic and commensal bacterial species that harbor antibiotic resistance 32 genes (ARGs), such as those encoding for ampicillin-degrading β-lactamases. We investigated 33 whether harmless autochthonous bacteria might degrade orally administered antibiotics, 34 thereby impairing their ability to combat intestinal pathogens. Here we report that antibiotic 35 degradation by a resident intestinal strain of E. coli reduces the effectiveness of oral ampicillin 36 against two intestinal pathogens, L. monocytogenes and C. difficile, resulting in increased 37
intestinal and systemic bacterial burden. We demonstrate that expression of ARGs by non-38 pathogenic members of the gut microbiota shields antibiotic-sensitive pathogens and enhances 39 their expansion and dissemination. 40 41 42
Observation 43 Antibiotic administration has markedly reduced the morbidity and mortality associated with 44 bacterial infections in the pre-antibiotic era. Increasing antibiotic-resistance in pathogenic 45 microbes, mediated in part by acquired genes that encode antibiotic-degrading enzymes, 46 represents a major threat to human health (1) . 47
The gut microbiota contains trillions of commensal bacteria that can also harbor 48 antibiotic resistance genes (ARGs) (2). Notably, antibiotic exposure can increase ARG gene 49 representation and expression by the gut microbiota (3). Horizontal ARG transfer represents a 50 mechanism by which drug-sensitive microbes can acquire resistance, e.g. by acquisition of 51 genes encoding antibiotic-degrading hydrolases (4, 5). Thus, it is possible that commensal 52 bacterial species transfer ARGs to intestinal pathogens upon antibiotic exposure in the gut 53 lumen. However, another possibility is that production of antibiotic-degrading enzymes by the 54 resident microbiota protects otherwise drug-sensitive pathogens in trans, thereby facilitating 55 their replication and spread in the host. 56
To test this hypothesis in a controlled system, we reconstituted germ-free (GF) mice 57 with an E. coli strain, utilized here as a model commensal, that expresses either a WT form of β-58 lactamase (TEM-1) or an inactive point mutant (hereby referred to as WT BLA or mut BLA, 59 respectively) ( Figure 1A ) (6). This approach yielded cohorts of mice that, with the exception of 60 one codon, harbor identical genomes, thus excluding differences in microbiota functions (e.g., 61 immune activation, colonization resistance, etc.) that are not related to the β-lactam 62 degradation. 63
Although WT BLA and mut BLA E. coli reached identical luminal bacterial densities in 64 reconstituted mice, a colorimetric assay confirmed that only the intestinal content of mice 65 reconstituted with WT BLA E. coli retained the capacity to hydrolyze β-lactams (Figure 1 B, C). 66
One week after reconstitution, mice were orally infected with the foodborne pathogen Listeria 67 monocytogenes 10403s (Lm). Lm is highly sensitive to β-lactam antibiotics and can expand in 68 the gut lumen of mice that lack colonization resistance (7). Mice were then administered 69 ampicillin on day +1 and +2 post Lm infection and sacrificed on day +3. As expected, Lm reached 70 identical densities in the intestines of WT BLA or mut BLA E. coli reconstituted mice on day +1, 71
indicating that the 2 E. coli strains did not differ in their inability to provide colonization 72 resistance against Lm. However, we found significantly higher Lm burden in multiple organs in 73 mice harboring WT BLA E. coli on day +3, consistent with the notion that β-lactamase-74 dependent ampicillin degradation shielded Lm from the therapeutic antibiotic's action. 75
To exclude the possibility that Lm might have acquired resistance to ampicillin via horizontal 76 gene transfer, we inoculated single Lm colonies recovered from the cecal content of WT BLA E. 77 coli-reconstituted, Lm-infected mice, into liquid medium either in the presence or absence of 78 ampicillin. Notably, none of the inoculated Lm colonies grew in the presence of ampicillin, in 79 contrast to WT BLA-expressing E. coli colonies recovered from the same mice ( Figure 1F ). 80 Furthermore, none of the Lm colonies tested positive for the presence of the β-lactamase gene, 81 which was uniformly detected in colonies of WT BLA E. coli by PCR ( Figure 1G ). 82
To confirm that the increased Lm burden observed above was due to antibiotic 83 degradation by resident E. coli, we collected the cecal contents of mice reconstituted with 84 either WT BLA or mut BLA E. coli and treated with ampicillin in the drinking water for two 85 consecutive days to allow for luminal accumulation of the antibiotic. Inoculation of Lm into 86 serial dilutions of the cecal content supernatants revealed that the cecal contents from mice 87 reconstituted with mut BLA E. coli had a higher inhibitory capacity compared to cecal contents 88 recovered from mice reconstituted with WT BLA E. coli ( Figure 1G and Supplementary Figure 1) . 89
Since the presence of active β-lactamase was the only bona fide difference between the cecal 90 contents of the two cohorts of mice, we conclude that the microbiota-encoded enzymatic 91 activity curtailed the efficacy of ampicillin treatment against Lm. 92
93
To expand our observations beyond the Listeria model, and to assess whether commensal-94 mediated antibiotic degradation may represent a mechanism that is relevant to other infectious 95 agents, we adapted our experimental strategy to an established C. difficile infection model (8) 96 ( Figure 2A) , an important intestinal pathogen that is also sensitive to ampicillin (Supplementary 97 Figure 2 ). Of note, this model allowed us to investigate the relevance of our findings in a setting 98 where expansion of an antibiotic-resistant microbe takes place following antibiotic-mediated 99 depletion of the intestinal microbiota, a common occurrence in hospitalized patients (9) . 100
Similar to the results obtained with Lm, we observed indistinguishable levels of expansion for 101 both E. coli and C. difficile on day +1 after reconstitution or infection, respectively, in all groups 102 of mice ( Figure 2B , C). In agreement with our previous findings, the C. difficile burden was 103 significantly reduced by ampicillin treatment in mice reconstituted with mut BLA E. coli, but not 104 in mice reconstituted with WT BLA E. coli ( Figure 2D ). Direct comparison of the ampicillin-105 treated mice confirmed a significantly higher burden in mice whose intestinal flora had the 106 capacity to hydrolyze β-lactams ( Figure 2D ). 107 108 These findings suggest that ARGs expressed by commensal bacteria can shape the chemical 109 niche of the intestine and confer an apparent antibiotic resistant phenotype to pathogens in 110 trans, without direct acquisition of ARGs by the pathogenic microbe. We refer to this activity as 111 commensal-mediated pathogen shielding. Using two different infection models, we show that 112 production of β-lactamases, a prototypical antibiotic resistance factor, by resident intestinal 113 microbes can significantly reduce the effectiveness of ampicillin treatment, thereby generating 114 a safe environment in which otherwise sensitive pathogens are shielded from this drug. 115 Importantly, previous studies in healthy volunteers demonstrated that upon treatment with 116 cephalosporins, subjects harboring BLA-producing commensal strains, unlike BLA-negative 117 subjects, had undetectable concentrations of the drug in the feces and maintained a rich 118 microbiota, providing evidence that BLA concentrations sufficient to inactivate antibiotics are 119 commonly achieved in humans (10, 11). 120 121 Whether or not ARGs enrichment within the gut microbiota is detrimental to host health is a 122 complex question, and the answer is likely to be context-dependent. 123
For instance, oral administration of recombinant beta lactamase or BLA-producing bacteria was 124 shown to preserve the integrity of the microbiota following parenteral administration of beta-125 lactam antibiotics in animal models, without affecting drug concentration in the serum (12-17). 126
These approaches were shown to be advantageous in that they preserved colonization 127 resistance against pathogens (12) (13) (14) (15) (16) (17) . 128
On the other hand, early work (reviewed in (18)) revealed that beta-lactamase-producing, non-129 pathogenic bacteria, can hinder the efficacy of penicillins in vitro and in vivo, using models of 130 subcutaneous and tonsil infection. Clinical data also suggested that the presence of one beta-131 lactamase-producing bacterial strain at the site of infection could enhance persistence of a 132 pathogen upon antibiotic treatment (19) . In these settings, members of the Bacteroides genus, 133 among the most highly represented genera in the human intestine(20), were also identified as 134 Consistent with these observations, our laboratory recently showed that a few bacterial strains, 136 out of the dozens composing the microbiota of a mouse colony treated with ampicillin for over 137 8 years, had the capacity to hydrolyze ampicillin, while the other bacterial strains, in isolation, 138 remained sensitive to ampicillin and thus were protected in trans by a minor subset of the 139 microbiota (21)(see Figure 4A in (22)). 140
141
In conclusion, we propose that commensal-mediated pathogen shielding can impair the 142 effectiveness of some antibiotic treatments during infection. While pharmacokinetic studies 143 have generally focused on antibiotic absorption, distribution, enzymatic modification, protein 144 binding and biliary/renal clearance, the role of microbiota-mediated antibiotic degradation in 145 the gut lumen and its potential for dramatically impacting responses to antibiotic treatment has 146 received less attention. Our findings extend the recently uncovered broad capacity of the gut 147 microbiota to metabolize drugs, affecting their efficacy (23, 24) . Within this model, antibiotics 148 represent an additional class of xenobiotics that commensals can metabolize. 149
Our study suggests that presence or absence of commensal bacterial strains that inactivate Individual Lm colonies (28) or WT BLA E. coli colonies (4) from 4-5 different mice were 170 inoculated into BHI +/-ampicillin. OD was measured after o.n. culture. G) Colonies utilized for 171 the experiment depicted in F) were also subjected to PCR with primers specific for the TME-1 β-172 lactamase gene or p60 (Lm positive control). Shown are results for 6 Lm colonies and 1 E. coli 173 colony; identical results were obtained for all tested colonies. H) The cecal content of WT mice 174 reconstituted with either WT or mut BLA E. coli and administered ampicillin in drinking water 175 for two days was serially diluted and inoculated with Lm. Lm growth was assessed after o.n. 176 culture by measurement of OD and direct plating (one representative plate shown on the left). 177
Plotted values correspond to the first dilution allowing for detectable Lm growth (with 1 178
indicating Lm growth at all dilutions) (n=3, shown is mean ± SD). Similar results were obtained 179 utilizing antibiotic-treated, E. coli-reconstituted animals (see Supplementary Figure 1 
Mouse Husbandry 210
All experiments using wild-type mice were performed with C57BL/6J female mice that were 6-8 211 weeks old; mice were purchased from Jackson Laboratories. Germ-free (GF) mice were bred in-212 house in germ-free isolators. Following reconstitution mice were housed in sterile, autoclaved 213 cages with irradiated food and acidified, autoclaved water. All animals were maintained in a 214 specific-pathogen-free facility at Memorial Sloan Kettering Cancer Center Animal Resource 215
Center. Experiments were performed in compliance with Memorial Sloan-Kettering Cancer 216
Center institutional guidelines and approved by the institution's Institutional Animal Care and 217 Use Committee. 218 219
Generation of E. coli strains 220
Plasmids encoding for WT TEM-1 βlactamase (pDIMC8-TEM1) or mutated TEM-1 βlactamase 221 (pDIMC8-TEM1 W208G) were extracted from the RH06 and RH09 E. coli strains, published 222 elsewhere (6), gel-purified and utilized for transformation of Stellar competent cells (Takara 223 Bio) according to manufacturer's instructions. The resulting strains were utilized for 224 experiments throughout this study. Of note, the plasmids conferred resistance to 225 chloramphenicol, and while expression of the TEM-1 gene was placed under the regulation of a 226 tac promoter, we did not induced it by IPTG treatment, but rather exclusively relied on leaky 227 transcription of the gene, to produce more physiologically-relevant conditions. 228 229 Antibiotic treatment, reconstitution and infections 230 GF mice were gavaged with either of two strains of E. coli, encoding for a functional or a point-231 mutated version of TEM-1 β-lactamase, respectively. 1 week post reconstitution mice were 232 gavaged with 10 9 CFUs of L. monocytogenes (Lm) strain 10403s and administered 1 mg of 233 ampicillin (Fisher) by oral gavage daily for 2 consecutive days. Animals were euthanized at day 3 234 post infection. Reconstitution of WT mice with E. coli strains for in vitro experiments involving 235 dilution of cecal content, mice were treated for 3 days with metronidazole and vancomycin in 236 drinking water (0.5 g/l), left on regular water for 1 day, and then gavaged with the appropriate 237 E. coli strain. 1 week post reconstitution mice were treated with ampicillin in drinking water 238 (0.5 g/l) for two days prior to being euthanized. 239
For C. difficile infection experiments, WT C57Bl/6 mice were administered a combination of 240 metronidazole, neomycin and vancomycin (0.25 g/l each) in drinking water for 3 days, and 24h 241 post antibiotic regimen cessation were injected i.p. with clindamycin (200 μg). On the following 242 day mice were reconstituted with either WT or mut BLA E. coli (5x10 4 CFUs) and 200-500 spores 243 of C. difficile strain VPI10463 (ATCC #43255). 244
CFUs enumeration and Selective plating 246
L. monoctogenes was identified through plating of serial dilutions of homogenized organs 247 (prepared as described elsewhere (7)) or fecal material (resuspended 100 mg/ml in PBS) onto 248 BHI plates supplemented with streptomycin (100 μg/ml) and nalidixic acid (50 μg/ml). 249 E. coli CFUs were enumerated following plating of serial dilution of fecal material onto LB plates 250 supplemented with chloramphenicol (50 μg/ml). E. coli CFU numbers obtained from plating of 251 ex-GF mice at day of infection onto LB plates (not supplemented with antibiotics) yielded 252 identical numbers, indicating that plasmids carrying CM resistance cassette as well as the 253 WT/mut BLA gene were maintained even in the absence of any selective pressure. 254
For detection of C. difficile, fecal pellets or cecal content were resuspended in deoxygenated 255 phosphate-buffed saline (PBS), and ten-fold dilutions were plated on BHI agar supplemented 256 with yeast extract, taurocholate, L-cysteine, cycloserine and cefoxitin at 37°C in an anaerobic 257 chamber (Coylabs) overnight. 258 259 Lm culture in cecal content 260 Cecal contents were recovered from E. coli reconstituted WT or GF animals, resuspended in PBS 261 at 300 mg/ml (WT) and spun down at 3000 rpm for 10'. Serial 1:2 dilutions of the resulting 262 supernatant were generated using PBS and 100 μl of each dilution were plated in replicate in 263 flat bottom 96 well plates. An equal volume of BHI medium supplemented with streptomycin 264 (200 μg/ml) and nalidixic acid (100 μg/ml) acid (to prevent growth of residual E. coli) containing 265 100-1000 CFUs Lm 10403s, was added on top. Lm for this assay was prepared by re-inoculating 266 an overnight culture in liquid BHI at 37°C on shaker, until logarithmic phase of growth was 267 reached (OD=0.1-0.4). After an overnight incubation at 37°C, the plate was assayed by OD 600 268 reading and individual dilutions plated onto BHI-Strep-NA plates for assessment of Lm growth. 269
Normalized inhibition index was calculated as 1/first dilution allowing for Lm growth, with the 270 initial dilution being 1:2 to take into account the addition of a volume of BHI equivalent to that 271 of the medium. 
